MARKET

ITCI

ITCI

Intra-Cellular Therapies
NASDAQ
65.56
+0.24
+0.37%
Opening 10:13 05/21 EDT
OPEN
65.10
PREV CLOSE
65.32
HIGH
65.66
LOW
65.00
VOLUME
61.41K
TURNOVER
0
52 WEEK HIGH
84.89
52 WEEK LOW
45.50
MARKET CAP
6.92B
P/E (TTM)
-56.8900
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ITCI last week (0513-0517)?
Weekly Report · 1d ago
Weekly Report: what happened at ITCI last week (0506-0510)?
Weekly Report · 05/13 09:24
Maintained Buy Rating on ITCI Shares Amidst Strong Caplyta Revenue and Positive MDD Study Outlook
TipRanks · 05/10 06:08
Intra-Cellular Therapies: A Buy Rating on Solid Financials and Promising Drug Development
TipRanks · 05/10 05:34
Buy Rating Affirmed on Intra-Cellular Therapies Amid Strong Sales and Promising Clinical Trials
TipRanks · 05/10 05:18
Analyst Ratings For Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company that develops drugs for treating diseases of the central nervous system. The company has an average price target of $91.94 and a 12-month growth rate of 50%. 18 analysts have evaluated the company in the last three months. Intra- cellular therapies has a high estimate of $120.00.
Benzinga · 05/08 20:00
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
NASDAQ · 05/08 15:43
Intra-Cellular Therapies: A Strong Buy on Robust Financials and Promising Caplyta Prospects
TipRanks · 05/08 11:29
More
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Webull offers Intra-Cellular Therapies Inc stock information, including NASDAQ: ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.